Get started
TAKEDAPH DRN EDTAKEDAPH DRN EDTAKEDAPH DRN ED

TAKEDAPH DRN ED

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

TAKP34 trade ideas

TAK : SQUARE ROOT / POSITION TRADEThe Square Root set-up appears in large cap stocks that underwent capitulation. Because large caps are heavily traded, the high liquidity reduces sharp movements. This set-up is best for position trading and usually is a sweet spot for establishing a core position on a stock that potentially has long runway for an uptrend. Tailwinds: There are reasons to be optimistic for the longer-term growth with Takeda also being a diversified COVID vaccine play. Exploring further, the company has a multi-thronged approach to the problem, first as a treatment developer undergoing clinical Phase 2 trials using plasma technology, second as a manufacturer through a license agreement with Novavax's (NASDAQ: NVAX) COVID-19 vaccine candidate and finally, as a distributor in a three-way agreement with the Japanese government for Moderna's (NASDAQ: MRNA) vaccine. Source : Chetan Woodun, SeekingAlpha read full article here : seekingalpha.com
NYSE:TAKLong
by TradingMavericks
2
Big Bull Run, 30+ short term, 50+ long term 30 within month 50+ within year Takeda has made significant moves in the development of it's global pipeline. From the MASSIVE moves with various COVID vaccine manufacturers, to acquiring smaller Immunology biotech startups, and increase in Boston research sphere. I am the most bullish on Takeda purely from a fundamental standpoint. Institutional ownership is low compared to other pharma's (AZN ~15%, Pfizer 66%), which would be extremely worrying, except I view it as less big movers to the stock, more tiny movers, which can make volatility rather high, but if this recent consumer-approach of holding longer on to a stock, then I take this over the risk of BoA deciding it isn't worth it to them anymore. Furthermore, ARK has >20million shares, and we can all agree that Cathie Wood is a genius. They just brought on their first non-Japanese CEO, who has publicly announced a more global-centric development platform. This isn't a sudden change in Takeda, this is the culmination of that shift. They have been stepping more and more into the Boston science sphere, with more and more of that to be expected as they continue to build up their Boston staff. As of the time of writing, TAK sits at 18.86 with a 42 cent change in share price with todays announcement of very positive phase 3 clinical trial news, and J&J COVID vaccine manufacturing deal. I expect very big gains very soon, as investors find more and more news at EOD research cycle, followed by the pump and dump crew hopping on. As new analyst outlooks come out, I expect a $50+ evaluation, possibly mimicking recent biotech movements of 100% very quickly. This is my first published idea, I would love feedback! If you want to see any additions, such as the pipeline and disease relevance data, I can definitely add that for Takeda. I plan to continue publishing in smaller biotech's, as I am just starting to get into investing my own money, and my scientific background, namely in the Boston-biotech sphere. This is in no way financial advise, and as I am new to price predictions, I am following very very basic rules, but I will refine and develop my personal algorithm for price evaluations due to real market fundamentals such as drug market valuations, etc. Thank you for your time, and please remember, I am not a financial advisor, this is my personal biased view on this company's stock valuation, please do your own due diligence so you are making decisions based on your own knowledge and beliefs!
NYSE:TAKLong
by DoctorFaustus
1
4502 (TSE) - Be CarefullGreetings Humbled, we would like to thanks for your support who has already liked, commented and followed us. Your support, strengthens us, to help in analyzing the market. If you have any questions, do not be hesitant to send us message (inbox). Our Service : Signal recomendation, Trading Course, Portofolio Consultation for multi asset such as Stock, FX, Derivative, Crypto, etc. If u are newbie on the stock market, do not be hesitant to contact me at Private Message. Our Job is to make u Prof trader and proftable trader. Strategy - Please care for Money Management - Have a good psychology - Do not be hurry to open position - Evaluate and upgrade your trading plan 4502 (TSE) - Be Carefull
TSE:4502
by MultiAssetX
TAK - Takeda Pharma - TO THE MOON? - Major Covid 19 Discovery Researchers tout 'major scientifc discovery' in $14M study for COVID-19 treatment www.cbc.ca Close to 4,500 people participated in the study, lead researcher calls findings 'substantial' and 'robust' CBC News · Posted: Jan 23, 2021 4:07 PM ET | Last Updated: January 23 The $14-million study was funded by the Quebec government and several organizations. (Ivanoh Demers/Radio-Canada) Nearly a year after launching a clinical study into a potential COVID-19 treatment, researchers with the Montreal Heart Institute suggest a widely available anti-inflammatory drug is effective in helping people stay away from hospitals and survive the disease. Nearly 4,500 people took part in a study that's led to what the researchers are calling "a major scientific discovery." During the study, researchers found that colchicine reduced the chance of death or hospitalization by 21 per cent when compared to a placebo. That number went up when specifically looking at the pool of about 4,200 participants whose COVID-19 diagnoses were confirmed by a polymerase chain reaction (PCR) test. Within that group, researchers say colchicine reduced hospitalizations by 25 per cent and deaths by 44 per cent. They also found the drug helped cut the need for mechanical ventilation by 50 per cent. "These results are substantial, they are robust, and we believe are compelling to justify the use of the colchicine," said Dr. Jean-Claude Tardif, director of the Montreal Heart Institute's research centre. "I believe this will have a fairly swift impact on how we practice medicine for patients that have COVID and are not yet hospitalized." Researchers with the Montreal Heart Institute say their findings suggest colchicine reduces the chances of death and hospitalizations for someone with COVID-19. (Ryan Remiorz/The Canadian Press) The study, called COLCORONA, was launched last March and cost $14 million. It includes hundreds of subjects whose COVID-19 diagnoses were not confirmed by PCR tests because those tests were not as widespread at the time, Tardif said. Tardif also said the initial goal was to recruit 6,000 participants, but researchers settled on a lower number due to the urgency of the situation. "The beauty of colchicine is it's already available in pharmacies. So, if a physician reads this today, and has a patient that is at risk of complications, that physician can very well prescribe colchicine today," Tardif said. "This is the reason we felt compelled to alert the population and the medical community immediately about these findings." Researchers are preparing to publish their findings in a scientific journal. The study was funded by the Quebec government and several other organizations, and was carried out without contact, with participants from Canada, the United States, South America and South Africa remaining at home.
NYSE:TAKLong
by drchelsea1
7